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Abstract
We previously associated the cytoskeleton linker protein, Ezrin, with the metastatic phenotype of pediatric sarcomas,
including osteosarcoma and rhabdomyosarcoma. These studies have suggested that Ezrin contributes to the survival
of cancer cells after their arrival at secondary metastatic locations. To better understand this role in metastasis, we
undertook two noncandidate analyses of Ezrin function including a microarray subtraction of high- and low-Ezrin-
expressing cells and a proteomic approach to identify proteins that bound the N-terminus of Ezrin in tumor lysates.
Functional analyses of these data led to a novel and unifying hypothesis that Ezrin contributes to the efficiency of
metastasis through regulation of protein translation. In support of this hypothesis, we found Ezrin to be part of the
ribonucleoprotein complex to facilitate the expression of complex messenger RNA in cells and to bind with poly A
binding protein 1 (PABP1; PABPC1). The relevance of these findings was supported by our identification of Ezrin
and components of the translational machinery in pseudopodia of highly metastatic cells during the process of cell
invasion. Finally, two small molecule inhibitors recently shown to inhibit the Ezrin metastatic phenotype disrupted the
Ezrin/PABP1 association. Taken together, these results provide a novel mechanistic basis by which Ezrin may contrib-
ute to metastasis.
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Introduction
Osteosarcoma (OS) is the most common primary tumor of bone.
Despite effective control of the primary tumor and both neoadjuvant
and adjuvant chemotherapy, the development of metastases to the
lungs is the most common cause of death in OS patients. Further-
more, the long-term outcome for patients who present with meta-
static disease is grave. The development of new and effective
treatments based on a more thorough understanding of metastasis
biology is needed.
Toward this end, we previously identified Ezrin as a protein asso-
ciated with the metastatic phenotype of two highly metastatic pedi-
atric cancers: rhabdomyosarcoma and OS [1,2]. Since then, Ezrin
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expression has been linked to clinical outcome, clinical stage, or
histologic grade in a number of cancers including mammary carci-
noma, pancreatic carcinoma, cutaneous and uveal melanoma, uterine
carcinoma, breast carcinoma, and soft tissue sarcoma [3–9]. Ezrin is a
member of the ERM (Ezrin-Radixin-Moesin) protein family. Ezrin
functions as a linker protein connecting the actin cytoskeleton (Ezrin
C-terminus) to integral plasma membrane proteins (Ezrin N-terminus)
[10,11]. Ezrin is proposed to exist in a dormant form in which the
C-terminal tail binds to and masks the N-terminal FERM domain
[12,13]. Therefore, amino-terminal Ezrin interactions are critical in
determining not only the repertoire of proteins Ezrin can interact
with but also the corresponding cellular functions that may be pos-
itively or negatively affected. This linkage to the cell membrane
allows the cell to physically engage and potentially sense the tumor
microenvironment. This linker function makes ERM proteins
essential for many fundamental cellular processes, including the
determination of cell shape, polarity and formation of surface struc-
tures, cell adhesion, motility, cytokinesis, phagocytosis, and inte-
gration of membrane transport with signaling pathways [14–17].
The linkage also leads to efficient signal transduction through
membrane-associated proteins and receptors. In our previous studies
of Ezrin and OS metastasis, we found that Ezrin was not constitu-
tively phosphorylated but rather was dynamically regulated during
metastatic progression [18]. Ezrin was phosphorylated early after
cells arrived in the lung and again as they progressed into the lung
microenvironment. Indeed, high Ezrin expression provided an ad-
vantage to highly metastatic cells during this time, resulting in the re-
tention of greater cells in the lung compared with cells with low Ezrin
expression. We hypothesize that Ezrin protects cells against apoptosis
resulting from stresses faced by metastatic cells at critical periods during
metastatic progression, namely early after cells arrive at secondary sites
(Hong et al., unpublished observations). In addition and in support of
this hypothesis, we recently identified two small molecule inhibitors
that bind the N-terminus of Ezrin and inhibit the Ezrin-dependent
metastatic phenotype [19]. However, the mechanism(s) by which
Ezrin contributes to metastasis are still not understood.
To better define the role of Ezrin in metastasis, we undertook two
noncandidate analyses of Ezrin protein function. First, we conducted
complementary DNA (cDNA) microarray subtraction of high- and
low-Ezrin-expressing tumor cells to identify differentially regulated
genes, pathways, and processes. Microarray analysis revealed 124 genes
with greater expression in high-Ezrin-expressing cells. Functional anal-
ysis of this transcriptional signature suggested that the process of pro-
tein translation, specifically translation initiation, was significantly
associated with the Ezrin metastatic phenotype. Second, we used
tandem mass spectrometry (MS-MS) analysis to identify proteins in
tumor lysates that bound the N-terminus of Ezrin. Affinity chroma-
tography and curation of MS-MS data identified 138 Ezrin-binding
proteins. Functional analysis of these Ezrin-interacting proteins also
revealed a link to the protein translation machinery. The surprising
convergence of these noncandidate analyses of Ezrin function led to
the hypothesis that Ezrin may contribute to the metastatic phenotype
by modulating the efficiency of protein translation in tumor cells.
Whereas there were no quantitative differences in total protein syn-
thesis in high- and low-Ezrin-expressing cells, there was an Ezrin-
dependent effect on the ability to translate a messenger RNA (mRNA)
containing a structured 5′ untranslated region (UTR). As an explana-
tion for this role, we found Ezrin interacts with the 3′ UTR binding
protein, poly A binding protein 1 (PABP1; PABPC1), an association
that has not been previously described. Furthermore, two Ezrin-binding
small molecule inhibitors (NSC305787 andNSC668394) that decrease
the Ezrin-dependent metastatic phenotype also inhibited Ezrin/PABP1
interaction. The relevance of these findings was supported by our iden-
tification of Ezrin and components of the translational machinery in
cellular extensions of highly metastatic cells during the process of cell
invasion. Taken together, our results linking Ezrin to the process of pro-
tein synthesis are novel and provide a new perspective for understanding
how Ezrin contributes to the process of metastasis.
Materials and Methods
Cell Culture and Tissue Harvest
Characterization and maintenance of high-Ezrin/high-metastatic
K7M2-WT, K7M2-neo (vector clone), intermediate-Ezrin/intermediate-
metastasis AS13, and low-Ezrin/low-metastatic K12-WT, AS2.13,
AS2.15, AS1.52, AS1.46 cells have been previously described [1,20].
Human OS (HOS-MNNG, U2 and 143B) and Ewing sarcoma
(TC32) cell lines weremaintained inDulbeccomodified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum, L-glutamine
(2mM), streptomycin (100U/mL), and penicillin (100U/mL; Invitro-
gen, Carlsbad, CA). Ezrin antisense clones were cultured in media
containing G418 (Invitrogen). For affinity chromatography studies,
K7M2 cells were grown to 80% confluence and harvested by trypsiniza-
tion before injection to 4- to 6-week-old BALB/cmice by tail vein injec-
tion, as previously described [1]. The resultant pulmonary metastases in
mice were dissected from surrounding lung and frozen for later use.
Plasmids and Transient Transfection Assays
The Ezrin N-ERMAD (Ezrin-Radixin-Moesin association domain)
construct used for recombinant protein production has been previously
described [21]. The Stem-Loop-luciferase reporter construct (pcDNA-
SL-LUC) was kindly provided by Nancy Colburn [22]. For luciferase
reporter assays, 5 × 105 cells were seeded on six-well plates in complete
medium and transfected with 2.5 μg of pcDNA-SL-LUC using 7.5 μl
of TransIT-LT1 reagent (Mirus, Madison, WI). Protein was harvested
24 or 48 hours after transfection. Firefly luciferase expression from
pcDNA-SL-LUC was measured using the Luciferase Assay System
(Promega, Madison, WI) in a Victor3 luminometer (PerkinElmer,
Boston, MA).
Gene Silencing with Small Interfering RNA
The Ezrin small interfering RNA (siRNA) sequence was generously
provided by Natasha Caplen from the Gene Silencing Section of the
National Cancer Institute and manufactured along with a nonsilencing
negative control by Qiagen Corporation (Valencia, CA). The Ezrin tar-
get sequence was 5′-CAGGACTGATTGAATTACGGA-3′ beginning
at nucleotide 2149 of human Ezrin mRNA. The siRNA (50 nM final
concentration) was added to cultured cells using siLentFect reagent
(Bio-Rad, Hercules, CA). Ezrin suppression was verified using Western
blot analysis.
Western Blot and Immunoprecipitation
Cells were lysed in either RIPA buffer (Upstate Biotechnology,
Waltham, NY) plus protease and phosphatase inhibitor cocktail
(Roche, Basel, Switzerland), 1× sodium dodecyl sulfate (SDS) or cell
lysis buffer (Cell Signaling Technology, Danvers, MA). About 30 to
50 μg of protein was separated on Tris-glycine gels (Invitrogen) and
transferred to nitrocellulose or polyvinylidene fluoride. The following
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primary antibodies were used: eIF4E, ribosomal S6, ERM, phospho-
ERM, PABP1, and YB-1 (Cell Signaling); β-actin and Ezrin (Sigma-
Aldrich, St Louis, MO); RACK1, actinin, IQGAP1, annexin II,
and RAN (BD Biosciences, Sparks, MD); CLIC4 and CLIC1 anti-
bodies kindly provided by Dr Mark Berryman, Ohio University Col-
lege of Osteopathic Medicine; and AHNAK and Rab14 provided
by Dr Jacques Baudier, INSERM, Grenoble, France. Horseradish
peroxidase–conjugated secondary antibodies and SuperSignal West
Pico chemiluminescence substrate were used for detection (Pierce
Biotechnology, Rockford, IL). For immunoprecipitation analysis,
24 hours after plating, cells were treated with 10 μM NSC305787
or NSC668394 for 5 hours in serum-free DMEM. Cells were lysed
with buffer containing 50 mM HEPES, pH 7.9, 100 mM NaCl,
4 mM NaPP, 10 mM EDTA, 10 mM NaF, 1% Triton X-100, 2 mM
sodium vanadate, 1 mM PMSF, 2 μg/ml aprotonin, 2 μg/ml leupeptin,
and 1 μM calyculin A. Lysates were precleared with a 50% slurry of
protein G agarose resin and incubated overnight with 2 μl of Ezrin
antibody (no. E8897; Sigma-Aldrich). Antigen-antibody complexes were
selected with protein G agarose beads, washed three times, and analyzed
by SDS-PAGE.
cDNA Microarray Procedure
Total RNA was extracted from eight murine OS cell lines (K7M2-
WT, K7M2-neo, AS13, AS2.13, AS2.15, AS1.52, AS1.46, and K12)
for cDNA microarray experiments; RNA preparation and microarray
experiments were done as previously described [23]. The RNA
obtained from K7M2-neo (high-Ezrin transfection control) was used
as a reference (Cy3 labeled) in all two-color cDNA microarrray
experiments. Data normalization and principal component analysis
were performed as previously described [23,24]. The normalized
expression ratios of experiments (seven cell lines) versus control
(high-Ezrin control K7M2-neo) for this filtered list were obtained
for further analyses. Two criteria were used to identify genes of
interest. First, we selected the cDNAs with a mean expression ratio
of 0.7 to 1.3 in the high-Ezrin group. From this list of cDNAs, only
those with a mean expression ratio of greater than 2 or less than
0.5 in the low-Ezrin group were then selected. These filtering steps
yielded 181 cDNAs of interest, which were then analyzed by hierarchi-
cal clustering using Cluster software version 3.0 (Tokyo University,
Tokyo, Japan). The heat map was generated using Java TreeView1.0.8
(http://jtreeview.sourceforge.net). Expression analysis systematic ex-
plorer (EASE) analysis was performed as previously described [25].
In addition, BLAST2GO (http://www.blast2go.org) was used to de-
termine overrepresented GO terms attributed to Ezrin-interacting pro-
teins identified by affinity chromatography and MS-MS identification
[26]. Quantitative polymerase chain reaction analysis of select differen-
tially expressed genes was performed using total cellular RNA. Primers
were custom designed and synthesized by Invitrogen, and sequences
are available on request.
Ezrin N-ERMAD Affinity Chromatography
The generation and purification of recombinant Ezrin N-ERMAD
protein and purification have been described previously [27]. Meta-
static lung nodules were grossly dissected into pieces no larger than
2 × 2 mm, weighed and suspended in cold extraction buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100
protease inhibitors) at 5 ml/g of tissue. The tissue was homogenized,
sonicated, and centrifuged at 50,000g for 30 minutes, followed by
ultracentrifugation at 200,000g for 30 minutes. Ten milliliters of
tumor protein extract (5 mg/mL) was incubated with 100 μl of
Ezrin N-ERMAD or BSA-coated sepharose beads. Soluble Ezrin
N-ERMAD protein was added to selected reactions for competition.
Samples were incubated overnight at 4°C, washed eight times with
cold TBS/0.1% Triton X-100, and bound proteins eluted by boiling
in 2× SDS sample buffer.
Tandem Mass Spectrometry
After affinity chromatography as described, protein bands were
excised and subsequently subjected to in-gel tryptic digestion to
extract peptides [28]. Each peptide sample was desalted, lyophilized,
and resuspended in 0.1% formic acid for liquid chromatography–
MS-MS analysis using an Agilent 1100 capillary high-performance
liquid chromatography system (Agilent Technologies, Santa Clara, CA)
with a 10-cm integrated micro reverse phase liquid chromatography–
electrospray ionization emitter column, coupled online with a LCQ
Deca XP mass spectrometer (Thermo Fisher Scientific, Fair Lawn,
NJ). Peptides were eluted using a linear gradient of 2% mobile phase
B (acetonitrile with 0.1% formic acid) to 42%mobile phase B. The ion
trap-mass spectrometer was operated in a data-dependent MS-MS
mode in which the three most intense peptide molecular ions in the
MS scan were sequentially and dynamically selected for subsequent
collision-induced dissociation using a normalized collision energy of
35%. The mass spectra were acquired at the mass range of m/z 475
to 2000. The ion-source capillary voltage and temperature were set
at 1.7 kV and 180°C, respectively. The MS-MS data were used to
search the EBI UniProt Homo sapiens database (http://www.ebi.ac.
uk/integr8). Up to two missed cleavage sites were allowed during the
database search. The cutoff for legitimate identifications were charge
state–dependent cross-correlation (Xcorr) ≥ 2.0 for [M + H]
1+, ≥2.5
for [M + 2H]2+, and ≥3.0 for [M + 3H]3+ with delta correlation
(ΔCn) ≥ 0.10. Additional protein identification was carried out on a
4800 matrix-assisted laser desorption/ionization-tandem time of flight
(MALDI-TOF-TOF) analyzer (Applied Biosystems, Carlsbad, CA) in
reflector-positive mode and then validated in MS-MS mode. Select
MS-MS–identified Ezrin-interacting proteins were identified by sub-
tracting nonspecific interactors by subtracting peptides found to inter-
act with BSA and then for proteins not represented by two or more
peptides in the MS-MS data. Detected peptides were then prioritized
for assessment based on actual versus predicted molecular weight
(MW) and peptide coverage. Proteins with a MW observed/actual
between 0.7 and 1.5 were selected.
m7-GTP Cap Affinity Binding Assay
Cells were grown to ∼50% confluence and lysed, and the super-
natant was precleared with 50 μl of sepharose CL-4B beads (50/50
slurry in wash buffer 1). Samples were centrifuged and supernatant
transferred to a new tube where 50 μl of m7-GTP sepharose beads
(GE Lifesciences, Piscataway, NJ) were added. Negative control
reactions received sepharose CL-4B beads without m7-GTP coating.
Samples were washed twice with wash buffer 1 (20 mM Tris-HCl,
pH7.5, 150mMNaCl, complete protease, and phosphatase inhibitors)
and once with wash buffer 2 (20 mM Tris-HCl, pH 7.5, 300 mM
NaCl, complete protease, and phosphatase inhibitors). Bound protein
was eluted with 2× SDS sample buffer with heating.
Polysome Analysis by Sucrose Density Gradient Fractionation
Cells were grown in complete DMEM and harvested at ∼50%
confluence. Immediately before harvesting, cells were incubated with
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cycloheximide (200 μg/ml) for 10 minutes at 37°C. Samples were
then placed on ice and washed twice with ice-cold PBS. Cells were
then lysed in polysome lysis buffer (250 mM KCl, 10 mM Tris-
HCl, pH 7.4, 25 mMMgCl2, 0.5% NP-40, 0.5% sodium deoxycho-
late, 1 μg/μl RNasin, 200 μg/ml cycloheximide, EDTA-free protease
inhibitors [Roche, Indianapolis, IN], phosphatase inhibitors, and
nuclease-free water) and incubated on ice for 15 minutes followed
by centrifugation at 4°C for 10 minutes at 12,000g. EDTA (25 mM
final concentration) was added to the lysis buffer in place of Mg2+ for
control samples to disrupt ribosomes. Supernatant was layered on 15%
to 45% (wt/vol) sucrose gradients and centrifuged at 180,000g for
2.5 hours at 4°C. An ISCO Model 640 fractionator with a UV-6
absorbance monitor, 10-mm path-length flow cell, was used to measure
the optical density of the gradients at 254 nm in real time. A Dataq
model DU-158 analog-to-digital converter was used for data acquisi-
tion using Windaq software (Dataq Instruments, Akron, OH).
Enzyme-Linked Immunosorbent Assay
ELISA experiments were performed by coating a 96-well high-
protein-binding ELISA plate (M0661; Sigma) with 200 ng of recom-
binant Ezrin protein. Nonspecific binding sites were blocked with 4%
bovine serum albumin for 2 hours at room temperature. Five hundred
micrograms of total protein from K12-WT cell lysate was added and
incubated for 2 hours at room temperature. PABP1 bound to Ezrin was
detected using a PABP1 antibody (no. ab6125; Abcam, Cambridge,
MA) and a horseradish peroxidase–conjugated antimouse antibody
(Sigma-Aldrich). Finally, 2,2′-azino-di-3-ethyl-benzthiazline sulfonate
(Sigma-Aldrich) substrate was added, and the optical density at 405 nm
was measured after 15 minutes.
Protein Isolation from Pseudopodia and Cell Bodies
Protein was isolated from migrating pseudopodia (“feet”) and cell
bodies using the Pseudopodia Purification Kit (Chemicon International,
Temecula, CA) according to manufacturer’s instructions.
Results
Microarray Analysis Defines an Ezrin-Dependent
Gene Expression Signature
To define the Ezrin-associated metastatic phenotype at the level of
transcription, cDNA microarray subtraction of high- and low-Ezrin-
expressing OS cell lines was carried out. Three cell line clones with
high Ezrin expression, three with low Ezrin expression and one with
intermediate Ezrin expression were hybridized with the high-Ezrin
transfection control, K7M2-neo, in two-color cDNA microarray
experiments. One hundred eighty-one (181) genes were differentially
expressed (vs the high-Ezrin control) with 57 downregulated and 124
upregulated (Figure 1). As predicted, AS13, the cell line with inter-
mediate Ezrin levels showed intermediate expression (between high-
and low-Ezrin cell lines) of the 181 genes of interest. Characterization
of differentially expressed genes, based on non–mutually exclusive gene
ontology (GO) function assignment, was conducted using EASE anal-
ysis. It revealed several specific gene functions significantly over-
represented in the 181 genes of interest compared with the total gene
set of non–differentially expressed transcripts. Functions such as devel-
opment, microtubule cytoskeleton, cytoskeleton, and microtubule-
associated complex were expected based on existing knowledge of
Ezrin biology (Table 1). However, other functions were unexpectedly
found to correlate with Ezrin expression. For example, an area of bio-
logic interest not previously associated with Ezrin activity but highly
overrepresented in our analysis was protein translation. Translation,
translation initiation, and translation initiation factor activity were
Figure 1. Hierarchical clustering of 181 differentially expressed
cDNAs define the Ezrin phenotype. A 21k cDNA microarray sub-
traction of high (K7M2 WT, and AS 2.13), intermediate (AS13),
and low (AS 1.52, AS 1.46, and K12 WT) compared with a high-Ezrin
control (K7M2-neo). High-Ezrin-expressing cell lines (black) show
little to no difference in expression ratios compared with K7M2-
neo, whereas low-Ezrin-expressing cell lines (red) show marked
differences in expression. The intermediate-Ezrin-expressing cell
line, AS 13, falls predictably between the high- and low-Ezrin expres-
sion ratios. Expression differences from select microarray outliers
were validated at the protein level and by polymerase chain reaction
(data not shown). Characterization of 181 differentially expressed
genes, based on non–mutually exclusive GO function assignment,
was conducted using EASE (Table 1).
Table 1. Functions That Define the Ezrin Microarray Transcription Phenotype Ranked by
EASE Score.
GO Function EASE Score* Fisher Exact t Test
Development 1.89e − 02 3.53e − 02
Microtubule cytoskeleton 3.09e − 02 2.21e − 02
Endopeptidase activity 3.77e − 02 1.49e − 02
Cytoskeleton 4.52e − 02 6.52e − 02
Microtubule-associated complex 6.98e − 02 4.52e − 02
Translation initiation 7.30e − 02 4.70e − 03
Neuron differentiation 7.64e − 02 1.00e − 04
Polyamine metabolism 1.23e − 01 2.00e − 04
Translation 1.03e − 01 3.93e − 02
Translation initiation factor activity 1.05e − 01 1.52e − 02
Morphogenesis 1.11e − 01 1.33e − 01
Kinesin complex 1.21e − 01 8.37e − 02
Learning and/or memory 1.36e − 01 1.50e − 03
Peptidase activity 1.41e − 01 1.35e − 01
RNA binding 1.41e − 01 1.35e − 01
*The value or EASE score is based on sliding Fisher exact probabilities where an EASE score of less
than 1.0 suggests overrepresentation of a function. The 15 functions with the lowest scores are listed.
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overrepresented GO functions that were associated with the follow-
ing four genes: eIF4e, Ormdl2, eIF3S4, and eIF1AY. The increase in
eIF4e expression in high-Ezrin cell lines, K7M2-wt and K7M2-neo,
has been confirmed by Western blot (C. Khanna, unpublished obser-
vations, personal communication). This functional approach to the
analysis of our microarray data suggested the hypothesis that Ezrin
expression was associated with altered regulation of the translation
machinery in these OS cells.
Ezrin Affinity Chromatography Independently Identifies
Proteins Involved in Translation
In parallel to the microarray studies described, a noncandidate
proteomic-based evaluation of Ezrin included the identification of
Ezrin-binding proteins, using affinity chromatography followed by
MS-MS. The amino (N) terminus of Ezrin has previously been
shown to be involved in numerous protein-protein interactions while
the carboxy (C) terminus primarily binds actin. In addition, the C-
terminus of activated Ezrin primarily binds f-actin, whereas the
diversity of Ezrin N-terminal interactions is far greater. Therefore,
we chose to use the N-terminus for affinity chromatography experi-
ments to “capture” Ezrin-interacting proteins from OS tumor lysates.
The proteins identified using MS-MS were prioritized to eliminate
those proteins that nonspecifically bound to BSA and were not iden-
tified by multiple unique peptides in the MS-MS data (Figure W1).
This filtering algorithm yielded 138 proteins that bound Ezrin with
strong coverage in OS tumor lysates (Table 2). Western blot analysis
of selected proteins eluted from N-Ezrin sepharose beads validated
the MS-MS identification of putative Ezrin-interacting proteins
(Figure W2). Disruption of the actin cytoskeleton in the harvested
protein lysates using latrunculin B demonstrated the requirement of
actin for the observed interactions between most candidate proteins
and Ezrin (suggestive of indirect protein interactions with Ezrin).
RACK1, the protein translation-associated scaffolding protein, and,
to a lesser extent, Rab-14, the large GTPase trafficking protein, dem-
onstrated persistent strong elution from N-Ezrin beads after actin
disruption. A direct interaction between RACK1 and Ezrin could
not be demonstrated by coimmunoprecipitation with available anti-
bodies. Functional classification of the 138 direct and indirect Ezrin-
binding proteins included GO terms for membrane trafficking and
cytoskeleton that were expected based on known functions of Ezrin
(Table 3). In addition, proteins associated with translation and trans-
lation initiation were also enriched, including YB-1 (Y-box binding
protein 1), RACK1 (receptor for activated C-protein kinase), and
several eukaryotic translation initiation and elongation factors. To
the best of our knowledge, Ezrin has not previously been shown to
interact directly or indirectly with these proteins or to be associated
with the process of protein synthesis. Taken together, the results
from both noncandidate genomic and proteomic studies suggested
a novel link between Ezrin and the process of protein translation.
Functional Analysis of the Translation Machinery in OS Cells
Next, to determine the extent to which Ezrin expression correlated
with changes in global translation, we used sucrose density gradient
centrifugation to analyze and quantify polysome profiles from high-
and low-Ezrin-expressing cells. This approach allowed for quantifi-
cation of total protein and mRNA associated with free messenger
ribonucleoprotein complexes (mRNPs), individual ribosomal subunits
(40S and 60S), monosomes (80S), and actively translating polysomes
(mRNA containing more than two 80S particles). A global increase
in translation initiation would be expected to result in an increase in
the A254 signal intensity for the heavy polysome fractions (areas of
active protein translation). Quantification of the area under the peak
for fractions 8 to 20 (containing more than two ribosomes) revealed
no difference between the high- and low-Ezrin-expressing cell lines,
suggesting similar rates of global translation (Figure 2A). Cells treated
with thapsigargin, a well-characterized inhibitor of translation initia-
tion, demonstrated an expected shift in polysome profiles in both cell
lines. Given the similarities in global translational rates, we hypoth-
esized that differences may exist in the efficiency of translation
of specific mRNA, namely those containing complex 5′UTR
(Figure 2B). mRNA with complex 5′UTR have been shown to be
“weakly” translated compared with the majority of other mRNA
species. Numerous proto-oncogenes and antiapoptotic genes possess
5′UTRs that may form complex secondary structures. The rate-limiting
step in synthesizing peptides from these messages seems to be during
assembly of the preinitiation complex or initiation [29–32]. To model
the expression of such complex 5′UTRs, we expressed a luciferase
reporter with a hairpin/loop structure (δG = −44.8 kcal/mol) placed
upstream of a luciferase protein coding sequence in cells with high
and low Ezrin (Figure 2B). This stem-loop sequence was previously
shown to dramatically inhibit protein synthesis of the downstream
cistron [22]. Cells with more efficient translational machinery would
be expected to better translate the stem-loop reporter mRNA resulting
in increased luciferase activity. Indeed, cells with high Ezrin were able
to express this complex synthetic (weakly translated) reporter more
efficiently than cells in which Ezrin was suppressed. A similar correla-
tion in stem-loop luciferase activity was seen after siRNA-mediated
knockdown of Ezrin expression in human OS (HOS-MNNG,
U2OS, 143B), rhabdomyosarcoma (Rh30), and Ewing sarcoma
(TC32) cell lines (data not shown). Taken together, these results sug-
gest that Ezrin expression specifically correlates with an increase in the
ability to express an mRNAwith a complex 5′UTR, without changes to
overall protein synthesis.
To provide an explanation for how Ezrin contributes to the initiation
of protein translation, we analyzed OS cell lysates, again by sucrose
density gradient centrifugation, to determine the extent to which Ezrin
protein was present in fractions containing complete, intact ribosomes
(80S monomers) as well as actively translating polysomes (Figure 3A).
Western blot analysis of Ezrin and previously identified proteins linked
to translation was conducted on protein isolated from each fraction. As
shown in Figure 3A, PABP1 and RACK1 were found in fractions con-
taining ribosomal subunits, monosomes, or polysomes and undetect-
able in the free mRNP fractions. This is consistent with previous
reports of RACK1 as a core ribosome-binding protein and PABP1’s
role in binding the poly A tail of mRNA as part of the protein trans-
lation complex [33,34]. eIF4E was detected mainly in fractions con-
taining free mRNPs and 40S-80S complexes consistent with its role
in translation before initiation. YB-1 was enriched in polysome frac-
tions consistent with its role as an mRNA binding protein involved
in regulating translation [35]. Ezrin was detected primarily in free
mRNP fractions as well as fractions corresponding to 40S, 60S and
80S particles (Figure 3A). However, Ezrin was not detected in high-
MW polysomes. Using an antibody that detects the ERM (Ezrin,
Radixin, Moesin) family members, including Ezrin, a similar pattern
of protein detection was seen (data not shown). These results suggest
that several functional pools of Ezrin may be present and that Ezrin
detected in fractions containing eIF4E, RACK1, PABP1, and/or YB-1
Neoplasia Vol. 14, No. 4, 2012 Ezrin Regulates Translation in Metastatic Cells Briggs et al. 301
Table 2. List of Ezrin N-ERMAD Interacting Proteins Identified by Affinity Chromatography and Tandem Mass Spectrometry.
Annotation Accession* Length (aa) Peptide† Matches Score‡
Ezrin (p81) (Cytovillin) (Villin 2) P15311 586 242 2.42
Tropomyosin 1 alpha chain P09493 284 68 4.18
DNA-binding protein A (NF-GMB) P16989 372 66 5.64
Moesin P26038 577 86 6.71
Annexin A2 (Annexin II) P07355 339 48 7.06
RACK1 P25388 317 41 7.73
Nucleolin (protein C23) P19338 707 81 8.73
PCNA/cyclin P12004 261 28 9.32
NAC alpha Q13765 215 22 9.77
YB-1 (CBF-A) P16991 324 29 11.17
ADP-ribosylation factor 1 P32889 181 16 11.31
RAN (Ran GTPase) P17080 216 19 11.37
Four and a half LIM domains protein 1 (FHL-1) Q13642 323 24 13.46
H326 protein Q12839 597 43 13.88
TLS-associated serine-arginine protein 1 Q96G09 173 12 14.42
EF-hand domain protein 2/Swiprosin 1 Q96C19 240 14 17.14
EBP50/NHERF-1 O14745 358 20 17.90
Radixin P35241 583 32 18.22
Thrombospondin 1 precursor P07996 1170 62 18.87
Desmin P17661 470 24 19.58
Tropomyosin alpha 3 chain (tropomyosin 3) P06753 284 14 20.29
Protein C14orf166 (CGI-99) Q9Y224 244 12 20.33
Calsequestrin P31415 390 18 21.67
Eukaryotic initiation factor 4A-I (eIF4A-I) P60842 406 18 22.56
Thioredoxin-like protein (32 kDa) O43396 289 12 24.08
Leucine-zipper protein FKSG13 Q9HAP4 390 16 24.38
TCP-1-alpha (CCT-alpha) P17987 556 22 25.27
Calgizzarin (S100C protein) P31949 105 4 26.25
ADP-ribosylation factor-like protein 1 P40616 181 6 30.17
E3KARP/NHERF-2 Q15599 337 11 30.64
Ribose-phosphate pyrophosphokinase II P11908 318 9 35.33
TCP-1-beta (CCT-beta) P78371 535 15 35.67
Polyadenylate binding protein 1 (PABPC1) P29341 636 17 37.41
ARP2/3 complex 16 kDa subunit (p16-ARC) O15511 151 4 37.75
Tropomyosin beta-chain (Tropomyosin 2) P07951 284 7 40.57
C-rich secretory protein-3 precursor (CRISP-3) P54108 245 6 40.83
Ras-related protein Rab-18 Q9NP72 206 5 41.20
Clathrin coat assembly protein AP50 (AP50) P20172 435 10 43.50
Lamin A/C (70 kDa lamin) P02545 664 15 44.27
Calcyclin P06703 90 2 45.00
Ribose-phosphate pyrophosphokinase I P60891 318 7 45.43
GTP-binding protein Rheb Q15382 184 4 46.00
alpha-centractin (Centractin) P61163 376 8 47.00
Clathrin coat assembly protein AP17 (AP17) P53680 142 3 47.33
CapZ alpha-1 P52907 286 6 47.67
TCP-1-theta (CCT-theta) P50990 548 11 49.82
Ras-related protein Rab-10 P61026 200 4 50.00
Eukaryotic initiation factor 4A-II (eIF4A-II) Q14240 407 8 50.88
Ras-related protein Rab-2A P61019 212 4 53.00
Ras-related protein Rab-14 P61106 215 4 53.75
Ubiquitin thiolesterase protein OTUB1 Q96FW1 271 5 54.20
S/T protein phosphatase PP1-alpha 1 catalytic P08129 330 6 55.00
GRP 78 P11021 654 11 59.45
Chloride intracellular channel protein 1 (CLIC1) O00299 241 4 60.25
Caspase-14 precursor (CASP-14) P31944 242 4 60.50
Selenoprotein H Q8IZQ5 122 2 61.00
PDZ-LIM protein mystique Q9H4L9 366 6 61.00
eIF-6 (B4 integrin interactor) P56537 245 4 61.25
Ras-related protein Rap-1A P10113 184 3 61.33
14-3-3 protein eta Q04917 247 4 61.75
26S protease regulatory subunit 7 P35998 433 7 61.86
Tropomyosin TPMsk3 (Fragment) CAH71266 248 4 62.00
NHP2-like protein 1 P55769 128 2 64.00
Adenylate kinase isoenzyme 1 P00568 194 3 64.67
TCP-1-delta (CCT-delta) P50991 539 8 67.38
TCP-1-epsilon (CCT-epsilon) P48643 541 8 67.63
Ras-related protein Rab-1A P11476 205 3 68.33
Ras suppressor protein 1 (Rsu-1) Q15404 277 4 69.25
CapZ alpha-2 P47755 286 4 71.50
GTP-binding protein Rit1 Q92963 219 3 73.00
26S protease regulatory subunit 6A P17980 439 6 73.17
C6.1A protein P46736 316 4 79.00
Sideroflexin 3 Q9BWM7 321 4 80.25
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Table 2. (continued )
Annotation Accession* Length (aa) Peptide† Matches Score‡
Vacuolar ATP synthase subunit H Q9UI12 483 6 80.50
14-3-3 protein tau P27348 246 3 82.00
14-3-3 protein zeta/delta P29312 246 3 82.00
TCP-1-eta (CCT-eta) Q99832 543 6 90.50
DNA replication licensing factor MCM5 P33992 734 8 91.75
CapZ beta P47756 277 3 92.33
Peroxisomal membrane protein PEX14 O75381 377 4 94.25
Rho-related GTP-binding protein RhoG P35238 191 2 95.50
p21-Rac1 (Ras-like protein TC25) P15154 192 2 96.00
GRP 75 (stress-70 protein, mitochondrial) P38646 679 7 97.00
SAR1a (COPII-associated small GTPase) Q9NR31 198 2 99.00
ARP2/3 complex 34 kDa subunit (P34-ARC) O15144 300 3 100.00
(SERCA1) (SR Ca(2+)-ATPase 1) O14983 1001 10 100.10
Ras-related protein Rab-35 (Rab-1C) Q15286 201 2 100.50
26S proteasome non-ATPase reg. subunit 2 Q13200 908 9 100.89
26S protease regulatory subunit 8 P47210 406 4 101.50
Ras-related protein Rab-11A (Rab-11) P24410 216 2 108.00
S/T PP2A, subunit B, B-alpha isoform (55 kDa) Q00007 447 4 111.75
alpha-1 catenin P35221 906 8 113.25
alpha-actinin 4 O43707 911 8 113.88
Ras-related protein Rab-33B Q9H082 229 2 114.50
S/T protein PP2A, subunit A, PR65-alpha P30153 589 5 117.80
14-3-3 protein gamma P35214 248 2 124.00
Chloride intracellular channel protein 4 (CLIC4) Q9Y696 253 2 126.50
Interleukin enhancer binding factor 2, 45 kDa CAI18796 390 3 130.00
Putative GTP-binding protein PTD004 Q9NTK5 396 3 132.00
GRP94 (endoplasmin tumor rejection antigen 1) P14625 803 6 133.83
Signal recognition particle receptor beta-subunit Q9Y5M8 271 2 135.50
Euk. Transl. Init. factor 3 subunit 6 (eIF-3e, p48) P60228 445 3 148.33
Cell division control protein 2 homolog (CDK1) P06493 297 2 148.50
GABA(A) receptor Q8N1C3 465 3 155.00
Fragile X MRRP-1 P51114 621 4 155.25
Protein kinase, interferon-inducible NP_003681 313 2 156.50
Protein C14orf120 Q8NEJ9 315 2 157.50
Protein arginine N -methyltransferase 5 O14744 637 4 159.25
Interferon-induced 56 kDa protein (IFI-56K) P09914 478 3 159.33
Sideroflexin 1 Q9H9B4 322 2 161.00
Mitotic checkpoint protein BUB3 O43684 328 2 164.00
Fascin (55 kDa actin bundling protein) (p55) Q16658 493 3 164.33
AH receptor-interacting protein (AIP) O00170 330 2 165.00
Serine hydroxymethyltransferase (SHMT) P34897 504 3 168.00
Annexin A1 (Annexin I) P04083 346 2 173.00
TCP-1-zeta-2 (CCT-zeta-2) Q92526 530 3 176.67
26S proteasome non-ATPase reg. subunit 3 (p58) O43242 534 3 178.00
Euk. Transl. Init. factor 3 subunit 6 interacting protein (HSPC021/HSPC025) Q9Y262 564 3 188.00
cAMP-PK type I-alpha regulatory chain (TSE1) P10644 381 2 190.50
Rev interacting protein Rip-1 Q13601 381 2 190.50
β-Catenin (PRO2286) P35222 781 4 195.25
26S protease regulatory subunit 6B P43686 418 2 209.00
Fragile X mental retardation 1 (FMR-1) (FMRP) Q06787 632 3 210.67
DNA replication licensing factor MCM4 P33991 863 4 215.75
Hexokinase, type I P19367 917 4 229.25
DNA replication licensing factor MCM7 P33993 719 3 239.67
CaM-kinase II delta chain Q13557 499 2 249.50
Flightless-I protein homolog Q13045 1269 5 253.80
6-phosphofructokinase, liver P17858 780 3 260.00
DNA replication licensing factor MCM3 P25205 808 3 269.33
β-COP P53618 953 3 317.67
CD2-associated protein (Cas-SH3 domains) Q9Y5K6 639 2 319.50
Protein disulfide isomerase A4 precursor (ERp72) P13667 645 2 322.50
Cullin homolog 4A (CUL-4A) Q13619 659 2 329.50
Vesicle-fusing ATPase P46459 744 2 372.00
Inhibitor of nuclear factor kappa B kinase beta O14920 756 2 378.00
gamma-COP Q9Y678 874 2 437.00
alpha-COP P53621 1224 2 612.00
*Accession number from the National Center for Biotechnology Information protein database.
†The number of MS peptides recovered matching identified protein.
‡Protein length divided by the number of MS peptides as an approximation of coverage.
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may represent a functionally important multiprotein complex associated
with translation.
To demonstrate that Ezrin cosedimentation with translation com-
ponents was not the result of interaction with nonrelated complexes
of a similar density, we treated lysates with EDTA before loading on
to sucrose density gradients. EDTA treatment chelates magnesium, a
necessary cofactor for ribosomal subunit integrity. As expected,
EDTA treatment caused a dramatic decrease in polysomes while
Table 3. Functional Assessment of Ezrin N-terminal Binding Proteins Identified by Affinity Chromatography and MS-MS.
Term P Adjusted P (FDR = 0.05)
GO molecular function (levels 4-9)
Unfolded protein binding (GO:0051082) 2.65e − 11 2.44e − 08
Actin binding (GO:0003779) 1.46e − 09 6.72e − 07
Magnesium chelatase activity (GO:0016851) 1.93e − 06 1.98e − 04
GTPase activity (GO:0003924) 4.54e − 06 3.81e − 04
GTP binding (GO:0005525) 1.25e − 05 9.65e − 04
Translation initiation factor activity (GO:0003743) 1.90e − 05 1.35e − 03
Cadherin binding (GO:0045296) 1.49e − 04 9.83e − 03
Ribose phosphate diphosphokinase activity (GO:0004749) 3.35e − 04 1.93e − 02
Protein C-terminus binding (GO:0008022) 9.73e − 04 4.82e − 02
ATPase activity (GO:0016887) 9.92e − 04 4.82e − 02
Protein N-terminus binding (GO:0047485) 9.33e − 04 4.82e − 02
GO cellular component (levels 4-9)
Actin cytoskeleton (GO:0015629) 2.81e − 10 6.43e − 08
Filopodium (GO:0030175) 1.20e − 08 1.38e − 06
Microvillus (GO:0005902) 4.18e − 08 3.19e − 06
Ruffle (GO:0001726) 1.29e − 07 4.99e − 06
Cytoplasmic membrane-bounded vesicle (GO:0016023) 3.89e − 07 1.27e − 05
Cytoskeletal part (GO:0044430) 8.09e − 07 2.06e − 05
Cytosolic part (GO:0044445) 1.16e − 06 2.42e − 05
Proteasome complex (GO:0000502) 4.24e − 05 8.08e − 04
Myofibril (GO:0030016) 6.23e − 05 1.10e − 03
Endomembrane system (GO:0012505) 8.10e − 05 1.24e − 03
Soluble fraction (GO:0005625) 1.60e − 04 2.16e − 03
Perinuclear region of cytoplasm (GO:0048471) 1.83e − 04 2.33e − 03
Uropod (GO:0001931) 5.00e − 04 6.03e − 03
Sarcolemma (GO:0042383) 5.39e − 04 6.17e − 03
Membrane coat (GO:0030117) 6.41e − 04 6.99e − 03
Apical plasma membrane (GO:0016324) 8.75e − 04 9.11e − 03
Eukaryotic translation initiation factor 4F complex (GO:0016281) 1.19e − 03 1.18e − 02
Sarcoplasmic reticulum (GO:0016529) 1.53e − 03 1.46e − 02
Extrinsic to membrane (GO:0019898) 2.09e − 03 1.84e − 02
Cytoplasmic vesicle part (GO:0044433) 2.65e − 03 2.25e − 02
Eukaryotic translation initiation factor 3 complex (GO:0005852) 3.38e − 03 2.77e − 02
Chloride channel complex (GO:0034707) 3.69e − 03 2.91e − 02
Dendritic shaft (GO:0043198) 4.87e − 03 3.60e − 02
Polysome (GO:0005844) 4.87e − 03 3.60e − 02
Small nucleolar ribonucleoprotein complex (GO:0005732) 5.42e − 03 3.88e − 02
Cell projection membrane (GO:0031253) 5.99e − 03 4.16e − 02
GO biological processes (levels 4-9)
Intracellular protein transport (GO:0006886) 5.00e − 09 4.05e − 06
Protein folding (GO:0006457) 2.87e − 08 1.55e − 05
Regulation of cytoskeleton organization (GO:0051493) 8.74e − 07 1.88e − 04
Regulation of actin polymerization or depolymerization (GO:0008064) 1.24e − 06 2.36e − 04
Actin filament polymerization (GO:0030041) 1.52e − 06 2.36e − 04
Negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle (GO:0051436) 3.15e − 06 3.82e − 04
Positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle (GO:0051437) 4.04e − 06 4.15e − 04
Actin polymerization or depolymerization (GO:0008154) 6.46e − 06 5.72e − 04
DNA replication initiation (GO:0006270) 1.28e − 05 9.85e − 04
Golgi vesicle budding (GO:0048194) 3.11e − 05 2.09e − 03
Vesicle targeting, to, from or within Golgi (GO:0048199) 4.12e − 05 2.69e − 03
Negative regulation of protein complex assembly (GO:0031333) 5.06e − 05 3.21e − 03
Actin filament bundle formation (GO:0051017) 7.81e − 05 4.67e − 03
Negative regulation of protein complex disassembly (GO:0043242) 9.53e − 05 5.55e − 03
Small GTPase-mediated signal transduction (GO:0007264) 1.62e − 04 8.94e − 03
Retrograde vesicle-mediated transport, Golgi to ER (GO:0006890) 2.06e − 04 1.09e − 02
Regulation of protein complex disassembly (GO:0043244) 2.25e − 04 1.13e − 02
Membrane to membrane docking (GO:0022614) 3.35e − 04 1.60e − 02
Negative regulation of cellular component movement (GO:0051271) 4.21e − 04 1.89e − 02
Regulation of proton transport (GO:0010155) 5.00e − 04 2.20e − 02
Vesicle organization (GO:0016050) 5.72e − 04 2.42e − 02
Nucleocytoplasmic transport (GO:0006913) 6.63e − 04 2.60e − 02
Striated muscle contraction (GO:0006941) 7.57e − 04 2.86e − 02
Modification-dependent protein catabolic process (GO:0019941) 8.43e − 04 3.13e − 02
Regulation of defense response to virus by virus (GO:0050690) 9.26e − 04 3.38e − 02
Body fluid secretion (GO:0007589) 1.02e − 03 3.61e − 02
Negative regulation of coagulation (GO:0050819) 1.31e − 03 4.48e − 02
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promoting a concomitant increase in the levels of dissociated ribo-
somal subunits (Figure 3B). In addition, Ezrin protein levels, along
with RACK1, decreased in 40S fractions. This suggested that cose-
dimentation of Ezrin in 40S fractions of non–EDTA-treated samples
(Figure 3A) was dependent on intact ribosomes, indicating that Ezrin
may be a part of the translation preinitiation complex. To investigate
this possibility, we used an approach to enrich for functional, cap-
bound translation initiation factors in K7M2 OS cell lysates. Altera-
tions in protein translation are often mediated by the expression and
availability of eukaryotic translation initiation factors, such as eIF4E,
or as a result of alterations in the regulation of signaling pathways.
eIF4E binds to the 7-methylguanosine “cap” present at the 5′ end of
all eukaryotic mRNAs and is central to formation of the translation
preinitiation complex. As shown in Figure 3C , eIF4E, was efficiently
captured from tumor cell lysates as were eIF4G and 4E-BP1. How-
ever, we were unable to detect the binding of Ezrin, or other ERM
family members using this approach. These results show that,
although Ezrin cosediments with factors involved in translation ini-
tiation, there is no direct interaction of Ezrin and cap-bound pro-
teins. We next asked if Ezrin might interact with proteins that
may stabilize the translational loop structure at the 3′ UTR of com-
plex proteins. Indeed, we found a direct interaction between Ezrin
and the poly A binding protein (PABP1; Figure 3, D and E ). In sup-
port of the interaction between PABP1 and Ezrin, the use of small
molecules that directly bind to Ezrin and inhibit metastasis in vivo
also blocked the interaction between PABP1 and Ezrin (Figure 3F )
[19]. Collectively, these findings provide new insights into the asso-
ciation of Ezrin with the ribonucleoprotein complex and may suggest
a role for Ezrin in the stabilization of the translational machinery
during its interaction with mRNA early during the initiation or
regulation of translation. Our data do not support a role for Ezrin
in active and ongoing mRNA translation.
The Cellular Relevance of Enhanced Protein Translation in
Metastatic Cells
The active, phosphorylated form of Ezrin is enriched at the cell
membrane, and it regulates signaling dynamics associated with actin
reorganization during cell motility [18]. To determine whether com-
ponents of the translation machinery colocalized with active Ezrin/
ERM family proteins in this context, we purified pseudopodia from
Figure 2. Ezrin expression does not influence global protein translation but contributes to the expression of complex mRNAs. (A) Polysome
analysis of high- (K7M2) and low- (AS 1.46) Ezrin-expressing cells was undertaken to assess active protein translation in cells. Cell lysates
were then layered onto 15% to 45% linear sucrose gradients for polysome analysis. Samples were fractionated and UV absorbance was
measured in real time (black line). The location of 40S and 60S ribosomal subunits as well as 80S ribosome monomers and larger MW
polysomes are resolved. Global inhibition of protein translation was observed after treatment of K7M2-WT cells with thapsigargin (Tg 1 μM;
red line). (B) Ezrin expression enhances expression of a synthetic protein (luciferase reporter) with a complex 5′UTR. High- (K7M2 and K7M2-
Neo) and low- (AS 1.46 and AS 1.52) metastatic/Ezrin-expressing murine OS cells were transfected with a construct designed to represent a
cap-dependent “weakly translated” protein with a complex 5′ untranslated region adjacent to the reporter fLUC gene (pcDNA-SL-LUC). Data
represent mean normalized luciferase units (normalized to K7M2-neo) from five distinct reporter experiments.
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migrating OS cells. Cells were plated on collagen/laminin–coated
membranes containing 0.2-μm pores. This selective pore size allows
invasion of pseudopod extensions through the pores in response to a
chemotactic gradient (e.g., high serum) while excluding cell bodies.
Western blot analysis was then undertaken for Ezrin and other proteins
involved in protein translation from invading pseudopodia (extracted
from the lower part of the membrane) or cell bodies (extracted from
the upper part of the membrane) of metastatic human and murine
Figure 3. Ezrin cosediments with messenger ribonucleoprotein (mRNP) complexes, ribosomal subunits and also interacts with PABP1.
(A) Ezrin is part of the ribonucleoprotein complex. Sucrose density gradient centrifugation was used to isolate and resolve messenger
ribonucleoprotein complexes. Western blot was used to determine the presence of Ezrin and other proteins known to be part of the
translational machinery in fractions spanning the entire gradient. Consistent with its role in translational initiation eIF4E was detected
mainly in fractions containing free mRNPs and 40S-80S complexes. RACK1, a core ribosome binding protein, was found in fractions
containing ribosomal subunits, monosomes, or polysomes and was not detectable in the free mRNP fractions. YB-1 was enriched in
polysome fractions consistent with its role as an mRNA binding protein. Ezrin was distributed mainly in free mRNP fractions (similar to
that of eIF4E) but also in smaller amounts with 40S, 60S, and monosomes. ERM family members including Ezrin showed a similar
overlapping pattern of protein migration (not shown). Polysome lysates were then dissociated with 25 mM EDTA treatment before
loading on sucrose density gradients. (B) EDTA treatment resulted in ribonucleoprotein dissociation. (C) Ezrin is not enriched in 5′ methyl
cap binding complex. An affinity matrix composed of 7-methyl-GTP covalently linked to sepharose beads was used to determine whether
Ezrin associates with the cap-binding structure. eIF4E and known eIF4E interacting proteins such as PABP1, eIF4G, and 4E-BP1 were
efficiently pulled down. Ezrin and other ERM family members were not found to be enriched with the cap binding complex. (D) Ezrin
interacts with the 3′ binding protein PABP1. Western blot immunoprecipitation demonstrated a direct interaction between Ezrin and
PABP1. (E) ELISA plate wells were coated with recombinant Ezrin. K12 cell lysate was used as the source of PABP1 protein. Ezrin-PABP1
complexes were detected using anti-PABP1 antibody. A meaningful signal was observed only in the presence of both Ezrin and PABP1.
Experiments were performed twice in triplicates and a representative result is shown. Graph represents the average of triplicate readings
with error bars indicating SD. (F) Ezrin-containing protein complexes in K7M2 cells were immunoprecipitated with an anti-Ezrin antibody.
The presence of PABP1 in this complex was confirmed by Western blot. Two small molecules, previously defined by their ability to bind
Ezrin and interrupt its interactions with other proteins [19], compound 8 (NSC305787) and compound 16 (NSC668394), blocked the
interaction between Ezrin and PABP1 compared with vehicle (DMSO)-treated condition without affecting immunoprecipitation efficiency.
Figure 3. (continued).
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OS cells (Figure 4). Samples were normalized so that equal amounts of
protein were loaded for each condition. As expected, phosphorylated
ERM family proteins were enriched in migrating pseudopodia. The rel-
ative levels of total ERM (unphosphorylated) protein were similar to
the cell bodies. Interestingly ribosomal S6, the 40S core protein,
RACK1, and eIF4E (proteins needed for the initiation of translation)
were all found in these invading pseudopodia. Levels of β-actin were
similar in both fractions. These data support the hypothesis that, during
metastatic progression, Ezrin may provide efficiency to metastatic cells
by allowing the translation of needed proteins at distinct points in time
and in distinct subcellular localizations (i.e., invadapodia). A corollary
of this hypothesis is that the inability of nonmetastatic cells to deliver
these needed proteins prevents them from successfully metastasizing.
Discussion
We previously identified the cytoskeleton linker protein, Ezrin, as
part of our effort to expand our understanding of the biology of
metastasis in pediatric sarcomas [1,20]. Since then, several groups
have identified associations between Ezrin expression and clinical
outcome in a variety of human cancers [9,36–40]. We previously
hypothesized that Ezrin enhances the ability of metastatic cells to
endure specific stresses related to metastatic progression [1]. The
inefficiency of metastasis is believed to be primarily influenced by
an inability of the majority of cancer cells to manage stresses that
are faced after cells arrive at distant secondary sites. High-Ezrin-
expressing cells are better able to resist this inefficiency early during
progression at secondary sites [41]. From these data, we hypothesized
that Ezrin expression allowed cells to rapidly adapt to the foreign
lung microenvironment and manage cellular stresses. However, it
has been unclear how Ezrin provided this advantage during the
process of metastasis. To address this question, we used two non-
candidate approaches to identify biologic processes affected by Ezrin
in OS cells. First, a genomic comparison of high- and low-Ezrin-
expressing OS cells resulted in a transcriptional signature of 181 genes
that correlated with high Ezrin expression. Functional analysis of
these cDNAs revealed unexpected enrichment of gene functions
related to protein biosynthesis. In parallel, we used affinity chroma-
tography in which the N-terminus of Ezrin was used to capture
putative Ezrin-interacting proteins present in tumor extracts. A total
of 138 bound proteins were identified by tandem mass spectrometry
and surprisingly, we again found enrichment of proteins associated with
protein translation and the translational machinery. These included
known RNA-binding proteins, translation initiation factors, the core
40S ribosomal subunit protein, RACK1, and the 3′ mRNA binding
protein, PABP1. Previous studies have demonstrated that cytoskeletal
dynamics and translation may be coregulated [42–46]. Furthermore, to
our knowledge, our study is the first to associate Ezrinwith protein trans-
lation and with elevated expression of components of the translation
machinery such as eIF4E.
Because eIF4E binding to the 5′ cap of cellular mRNA is considered
a major rate-limiting step in protein synthesis, increased expression in
the presence of Ezrin may provide a means for enhanced anabolic
processes such as tumor cell growth. Increased expression of eIF4E
has been shown to enhance translation of mRNA with a complex,
highly structured 5′ untranslated region [29]. Consistent with this idea,
expression of a weakly translated stem-loop reporter was increased in
high-Ezrin-expressing cells. We considered the possibility that
enhanced translation may be a general phenomenon affecting global
rates of protein synthesis. However, quantitative polysome analysis of
steady-state translation levels failed to reveal differences between high-
and low-Ezrin-expressing cells. In addition, polysome profiles from
physiologically stressed cells were also similar regardless of Ezrin levels.
Taken together, these data suggested that Ezrin might have an effect on
the translation of specific mRNAs with complex 5′ untranslated regions
rather than on global protein synthesis. This may not be surprising
because both high- and low-Ezrin-expressing OS cells are viable,
proliferate in vitro and yield similar primary tumor growth features
in vivo. The distinction among these cells is the inability of cells with
low Ezrin to metastasize [1]. A model of selective protein translation
describes proteins as either “strongly translated” or “weakly translated”
[47]. The strongly translated proteins undergo very limited regulation
of translation, whereas the “weakly translated proteins” are largely
maintained as stable mRNAs and await cues that activate the transla-
tional machinery to translate these complex proteins [48]. Common
among such “weakly translated proteins” is complexity in the 5′ and
3′ untranslated regions. Because it is energetically impossible to express
all proteins at all times, this proposed model suggests that cells in
dynamic environments activate the translational machinery in times
of need; as such, these “weakly translated proteins” undergo translation
only when they are most needed. Examples of “weakly translated pro-
teins” include proteins involved in acute phase responses and several
oncogenes [49].
Extending this hypothesis, we next asked whether Ezrin and com-
ponents of the translational machinery were present in subcellular
locations relevant to metastasis such as invading pseudopodia.
Indeed, we demonstrated the presence of phosphorylated forms of
Ezrin, and critical parts of the translational machinery (i.e., RACK1,
eIF4E) are present in these invading pseudopodia. These studies
support the notion that enhanced efficiency of metastasis may not
be limited to a kinetic advantage alone but may also involve the
Figure 4. Active Ezrin and elements of the translational machinery
are present in invading pseudopodia. Migrating highly metastatic
human and murine OS cells (143B and K7M2, respectively) were
plated on collagen/laminin–coated membranes containing 0.2-μm
pores. Lysates collected from the whole cell body (WCE) and
invading pseudopodia (feet) were collected. Western blot analysis
demonstrated expression of Ezrin and proteins involved in protein
translation in these invading cellular structures.
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opportunity to deliver proteins in the areas of greatest need during
metastasis. It is attractive to consider the dynamic needs of highly
metastatic cells and an efficiency in metastasis being conferred on
cells that are able to meet these needs through the delivery of neces-
sary proteins at specific times and locations within the cell [29]. Pre-
vious studies have shown that actin dynamics can alter translation by
directly affecting both transport of specific mRNA within the cell as
well as signaling to and from the protein synthesis machinery [45].
For example, during development, axons become polarized, migrat-
ing in response to chemotactic gradients. During this migration,
transmembrane receptors in the growth cone become activated stim-
ulating formation of actin-rich filopodia and lamellipodia. In this
context, the cytoskeleton serves as a scaffold for RNA binding pro-
teins, translation factors, and signaling intermediates, enabling the
spatiotemporal regulation of protein synthesis [50]. In light of our
current data and given the classic role of Ezrin as an actin-binding
protein, one can envision that a similar scenario may occur in migrating
and invading tumor cells during metastatic progression.
In further support of the link between Ezrin and protein translation,
sucrose density gradient fractionation of whole cell lysates revealed that
a portion of total Ezrin protein was present in fractions containing the
RNA binding proteins YB-1 and PABP1 as well as the cap binding
protein eIF4E and RACK1. These results provided a functional context
in which the majority of Ezrin was present in free mRNP fractions,
whereas a smaller portion was present in “lighter” ribosomal units.
The absence of Ezrin in more heavily weighted polysomes suggested
a role for Ezrin in the early phases of protein synthesis such as mRNA
transport, formation of the preinitiation complex, or initiation rather
than elongation or termination. These possibilities were further narrowed
down after we failed to detect the presence of Ezrin using 7-methyl
guanosine cap affinity chromatography to functionally enrich for com-
ponents of the cap-binding complex. In addition, eIF4A, eIF4G, and
eIF4E were all absent from Ezrin immunoprecipitates (data not shown).
However, one protein, identified by MS-MS, that did coimmunopreci-
pitate with Ezrin was poly-A binding protein (PABP1). Similar results
have been seen for binding of paxillin to PABP1 [50]. In addition,
paxillin/PABP1 complexes demonstrate nucleocytoplasmic shuttling in
a CRM1-dependent manner [51]. There have been some reports of
Ezrin localizing to the nucleus, and it is interesting to speculate that
PABP1 may play a role in nucleocytoplasmic shuttling of Ezrin as well
[52,53]. Although we cannot conclude from our current studies whether
Ezrin/PABP1 interaction is responsible for Ezrin’s role in translation and
metastasis, we have identified small molecule inhibitors, which block
their interaction and, importantly, also inhibit metastatic progression
in vivo [19]. Having established this phenotypic relevance, studies are
under way to characterize the nature of Ezrin/PABP1 interaction includ-
ing the dynamics and subcellular localization. In addition, future studies
will be aimed at identifying those endogenous mRNA, which may
coassociate with Ezrin/PABP1, specifically those with complex 5′UTR
as candidates for enhanced translation andwhich contribute tometastasis.
Collectively, these data provide support for a broader complex of
proteins that may collectively contribute to efficient protein transla-
tion. In our current report, we found that Ezrin interacts with
RACK1, by Ezrin affinity chromatography and cofractionation with
a portion of endogenous Ezrin in sucrose density gradient analysis. A
wealth of electron microscopy and crystal structure data have estab-
lished the location of RACK1 binding to the 40S ribosomal subunit
and functional analysis has revealed that RACK1 serves as a docking
site and scaffold for multiple proteins, including PABP1 and protein
kinase C (PKC), which regulate translation [33,54–56]. Interestingly,
we have previously shown that PKC isoforms coimmunoprecipitate
with Ezrin and mediate C-terminal Ezrin phosphorylation, believed
to regulate Ezrin’s activation in OS cells [18]. We hypothesize that
a complex involving Ezrin, PABP1, and PKC with close interaction
with RACK1 would be well positioned to efficiently regulate the
translational machinery in response to the stresses of metastasis.
Based on a confluence of functional data from genomic and proteo-
mic assessment of Ezrin function, we generated a hypothesis that Ezrin
contributes to the efficiency of metastasis by enhancing the process of
protein translation. In support of this hypothesis, we demonstrated that
Ezrin is part of the ribonucleoprotein complex, interacts with PABP1,
and may enhance the translation of specific proteins at specific subcel-
lular locations, critical to the metastatic phenotype. A potential clinical
impact of these findings is a biologic rationale for the use of inhibitors
of translation initiation, such as rapamycin and related synthetic
analogs, in the context of metastatic progression rather than solely for
established disease. Collectively, these data support new functions for
Ezrin in the metastatic phenotype of cancer and serve as a foundation
for studies that will elucidate the mechanisms by which this occurs.
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Figure W1. Ezrin-binding proteins resolved by affinity chromatography followed by tandem mass spectrometry. (A) Schematic diagram
describing affinity chromatography followed by tandem mass spectrometry approach. N-terminal Ezrin was purified and expressed on
sepharose beads. K7M2 murine OS primary tumor and pulmonary metastasis tissue, K7M2 murine OS cell lines, normal mouse lung,
and normal mouse muscle were applied to Ezrin beads for affinity chromatography in the presence of ATP. Eluted proteins were then
resolved by tandem mass spectrometry. (B) Identification of 138 OS Ezrin-interacting proteins. MS-MS peptides identified in tumor
tissue by MS-MS were filtered of nonspecific interacting proteins by BSA subtraction. Further subtraction of proteins was then based
the removal of proteins not identified by two or more unique peptides in the MS-MS data.
Figure W2.Western blot validation of selected tumor specific pro-
teins identified by Ezrin affinity chromatography. Eluted proteins
from BSA and N-terminal Ezrin affinity chromatography were
assessed by Western blot before and after the addition of ATP
(to optimally open Ezrin conformation) and latrunculin B (for dis-
ruption of the actin cytoskeleton). In the absence of ATP, the
closed conformation of Ezrin prevails. The majority of identified
proteins likely have indirect interactions with Ezrin through the
actin cytoskeleton, as supported by the absence of detectable
bands for most protein candidates after latrunculin B treatment.
Proteins that retained interaction with Ezrin after actin disruption
included IQGAP1, Ezrin, RACK1, and Rab 14.
